Small Tyrosine Kinase Inhibitors as Key Molecules in the Expression of Metalloproteinases by Solid Tumors

REFERENCES

• Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. 2002; 2: 91–100
   Google Scholar
• Roussidis A.E., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. The importance of c-kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. 2007; 14: 735–743
   PubMed Web of Science ®Google Scholar
• Kolibaba K.S., Drucker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta. 1997; 9(1333(3))F217–F248
   Google Scholar
• Kohn E., Liotta L. Molecular insights into cancer invasive strategies for prevention and intervention. Cancer Res. 1995; 55: 1856–1862
   PubMed Web of Science ®Google Scholar
• Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001; 37: S9–S15
   PubMed Web of Science ®Google Scholar
• Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61: 7196–7203
   PubMed Web of Science ®Google Scholar
• Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 1992; 6(14)3275–3582
   PubMed Web of Science ®Google Scholar
• Roussidis A.E., Mitropoulou T.N., Theocharis A.D., Kiamouris C., Papadopoulos S., Kletsas D., Karmanos N.K. STI571 as a potent inhibitor of growth and invasiveness in human epithelial breast cancer cells. Anticancer Res. 2004; 2: 1445
   Google Scholar
• Lin N.U., Winer E.P. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004; 6(5)204–210
   PubMed Web of Science ®Google Scholar
• Razandi M., Pedram A., Park S.T., Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 2003; 278(4)2701–2712
   PubMed Web of Science ®Google Scholar
• Seta K., Nanamori M., Modrall J.G., Neubig R.R., Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J. Biol. Chem. 2002; 277: 9268–9277.
   PubMed Web of Science ®Google Scholar
• Hazzalin C.A., Mahadevan L.C. MAPK-regulated transcription: a continuously variable gene switch?. Nat. Rev. Mol. Cell Biol. 2002; 3: 30–40
   PubMedGoogle Scholar
• Rosenthal E.L., Johnson T.M., Allen E.D., Apel I.G., Punturieri A., Weiss S.J. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res. 1998; 58: 5221–5230
   PubMed Web of Science ®Google Scholar
• Guo H., Zucker S., Gordon M.K., Toole B.P., Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J. Biol. Chem. 1997; 272: 24–27
   PubMed Web of Science ®Google Scholar
• Kanekura T., Chen X., Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 2002; 99: 520–528
   PubMed Web of Science ®Google Scholar
• Menashi S., Serova M., Ma L., Vignot S., Mourah S., Calvo F. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res. 2003; 63(22)7575–7580
   PubMed Web of Science ®Google Scholar
• Price D.J., Avraham S., Feuerstein J., Fu Y., Avraham H.K. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signaling through both PI 3-kinase and ERK 1, 2 pathways. Cell Commun. Adhes. 2002; 9: 87–102
   PubMed Web of Science ®Google Scholar
• Reddy K.B., Krueger J.S., Kondapaka S.B., Diglio C.A. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int. J. Cancer 1999; 82: 268–273
   PubMed Web of Science ®Google Scholar
• Sun J., Hemler M.E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001; 61: 2276–2281
   PubMed Web of Science ®Google Scholar
• Cáceres M., Guerrero J., Martínez J. Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. Exp. Cell Res. 2005; 10(309(1))229–238
   Google Scholar
• Kousidou O.Ch., Roussidis A.E., Theocharis A.D., Karamanos N.K. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res. 2004; 24: 4025
   PubMed Web of Science ®Google Scholar
• Kousidou O.Ch., Mitropoulou T.N., Roussidis A.E., Kletsas D., Theocharis A.D., Karamanos N.K. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int. J. Oncol. 2005; 26: 1101
   PubMed Web of Science ®Google Scholar
• Kousidou O.Ch., Tzanakakis G.N., Karamanos N.K. Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini-Rev. Med. Chem. 2006; 6: 331–337
   PubMed Web of Science ®Google Scholar
• Saaristo A., Karpanen T., Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000; 19: 6122–6129
   PubMed Web of Science ®Google Scholar
• Masuda M., Suzui M., Weinstein I.B. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 2001; 7(12)4220–4229
   PubMed Web of Science ®Google Scholar
• Shimizu M., Deguchi A., Hara Y., Moriwaki H., Weinstein I.B. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem. and Biophys. Res. Commun. 2005; 334: 947–953
   PubMed Web of Science ®Google Scholar
• Stahtea X.N., Roussidis A.E., Kanakis I., Tzanakakis G.N., Chalkiadakis G., Mavroudis D., Kletsas D., Karamanos N.K. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int. J. Cancer. 2007; 121(12)2808–2814
   PubMed Web of Science ®Google Scholar
• Toda D., Ota T., Tsukuda K., Watanabe K., Fujiyama T., Murakami M., Naito M., Shimizu N. Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. Anticancer Res. 2006; 26(1A)129–134
   PubMed Web of Science ®Google Scholar